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Background: Cyclic RGD peptidomimetics containing a bifunctional diketopiperazine scaffold are a novel class of
high-affinity ligands for the integrins αVβ3 and αVβ5. Since integrins are a promising target for the modulation of normal
and pathological angiogenesis, the present study aimed at characterizing the ability of the RGD peptidomimetic cyclo
[DKP-RGD] 1 proliferation, migration and network formation in human umbilical vein endothelial cells (HUVEC).
Methods: Cell viability was assessed by flow cytometry and annexin V (ANX)/propidium iodide (PI) staining. Cell
proliferation was evaluated by the ELISA measurement of bromodeoxyuridine (BrdU) incorporation. Network formation
by HUVEC cultured in Matrigel-coated plates was evaluated by optical microscopy and image analysis. Integrin subunit
mRNA expression was assessed by real time-PCR and Akt phosphorylation by western blot analysis.
Results: Cyclo[DKP-RGD] 1 does not affect cell viability and proliferation either in resting conditions or in the presence
of the pro-angiogenic growth factors VEGF, EGF, FGF, and IGF-I. Addition of cyclo[DKP-RGD] 1 however significantly
decreased network formation induced by pro-angiogenic growth factors or by IL-8. Cyclo[DKP-RGD] 1 did not affect
mRNA levels of αV, β3 or β5 integrin subunits, however it significantly reduced the phosphorylation of Akt.
Conclusions: Cyclo[DKP-RGD] 1 can be a potential modulator of angiogenesis induced by different growth factors,
possibly devoid of the adverse effects of cytotoxic RGD peptidomimetic analogues.
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Angiogenesis, the growth of new blood vessels as sprouts
or offshoots of the pre-existing microvasculature, is a
physiological event occurring in the development of or-
ganisms, wound healing and the reproductive cycle, but it
is also involved in pathologic processes such as inflamma-
tion, tumour growth and metastasis [1]. Angiogenesis can
be stimulated by a large number of pro-angiogenic cyto-
kines, such as vascular endothelial growth factor (VEGF),
tumour necrosis factor α (TNF-α), basic fibroblast growth
factor (bFGF) and interleukin-8 (IL-8) [2,3].* Correspondence: franca.marino@uninsubria.it
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unless otherwise stated.Among the proteins involved in the angiogenic
process, integrins play an important role by promoting
endothelial cell attachment and migration on the sur-
rounding extracellular matrix, cell to cell interaction and
intracellular signal transduction [4]. Integrins are hetero-
dimeric proteins composed of two non covalently associ-
ated α and β transmembrane glycoproteins; 18 α and 8 β
subunits that give rise to 24 possible distinct integrin
proteins [5,6]. Across their extracellular α/β subunit
interface containing the metal ion-dependent adhesion
site (MIDAS), integrins recognize and bind protein li-
gands through contiguous tripeptide sequences, the ma-
jority of which are present within flexible loop regions
and contain an acidic residue [7]. Several integrins, in-
cluding αV, α5β1 and αIIbβ3 integrins, recognize the Arg-
Gly-Asp (RGD) sequence in endogenous ligands. The
context of the ligand RGD sequence (flanking residues,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the integrin binding pockets determine the recognition
specificity and efficacy. These observations prompted many
research groups to investigate the use of conformationally
constrained cyclic RGD peptides and peptidomimetics as
active and selective integrin ligands [8,9]. One of these,
Cilengitide, namely cyclo-[Arg-Gly-Asp-D-Phe-N(Me)-Val]
is currently in phase III clinical trials as an angiogenesis in-
hibitor for patients with glioblastoma multiforme alone
[10] or in combination with other antiblastic drugs [11].
Recently, RGD compounds have been proposed also as tar-
geting ligands for integrins in order to better characterize
tumor neovascularisation [12]. Notwithstanding these re-
sults, the mechanism of RGD ligands in the inhibition of
angiogenesis is not yet fully understood, as significant
cross-talk exists in the regulation of angiogenesis between
integrin operated pathways and, for instance, VEGF recep-
tor pathways [13], and on these bases it has been proposed
that agents able to inhibit multiple pathways would have
important therapeutic potential [14].
Recently, some of us reported a new class of cyclic
RGD peptidomimetics containing a bifunctional diketo-
piperazine (DKP) scaffold, showing a low nanomolar af-
finity for integrins αVβ3 and αVβ5 [15,16]. The present
study is aimed at characterizing the ability of the cyclic
RGD peptidomimetic cyclo[DKP-RGD] 1 (Figure 1) to
affect cell viability, proliferation, migration and capillaryFigure 1 Structure of the peptidomimetic cyclo[DKP-RGD] 1.network formation in human umbilical vein endothelial
cells (HUVEC). In addition, the effect of cyclo[DKP-
RGD] 1 on mRNA expression of the integrin subunits
αV, β3 and β5, and on the phosphorylation of Akt, a
serine/threonine-specific protein kinase that plays a key
role in the regulation of vascular homeostasis and angio-
genesis [17] was also investigated.
Materials and methods
Reagents
The peptidomimetic cyclo[DKP-RGD] 1 was prepared ac-
cording to a published procedure [16]. Annexin V-FITC
Apoptosis Detection Kit I was purchased by Biosciences
(BD, Italy). RNA extraction was performed using Quiazol
reagent (Qiagen, Italy) and the quantitative real time RT-
PCR reaction were performed using Quantitatec reverse
transcription kit (Qiagen, Italy) and Quantitec sybr green
pcr kit (Qiagen, Italy). The amount of proteins for western
blot analysis were performed by the BCA protein Assay
Kit (Pierce Protein Biology, Rockford, IL, USA). Anti-AKT
and anti-pAKT, primary antibodies were purchased from
Cell Signalling (Cell signalling, Italy) and horseradish
peroxidase-conjugated goat anti-rabbit IgG secondary
antibody for western blot were purchased from Upstate
Biotechnology (Upstate Biotechnology, USA). The detec-
tion of the western blot membrane was performed by
using ECL plus Western Blotting Detection System pur-
chased from Amersham (Amersham, GE Healthcare Life
Science, MI, Italy). Propidium iodide (PI) solution was
purchased from Miltenyi (Miltenyi Biotec S.r.l., Bologna,
Italy). Matrigel Basement Membrane Matrix (10 mg/ml)
for the network formation assay was purchased from BD
(Becton Dickinson Italy, Milan, Italy). Cell proliferation
Biotrak Ver for the proliferation assay was purchased from
GEhealthcare (GeHealthcare, Uppsala, Sweeden). Human
umbilical vein endothelial cells (HUVEC) were obtained
from PromoCell (PromoCell Gmbh, Germany). The Endo-
GRO™ VEGF Complete Media Kit composed of EndoGRO
Basal Medium (SCME-BM) plus fetal bovine serum (FBS),
L-glutamine, heparin sulphate, rh-VEGF, rh-EGF, rh-
FGF2, rh-IGF-I and ascorbic acid, and the MF-Membrane
filters (3.0 μm) for the cell migration assay were purchased
from Millipore (Millipore S.p.A., MI, Italy). Recombinant
Human CXCL8/IL-8 was purchased from R&D (R&D
System, US, Europe).
Cell cultures
HUVEC were cultured in a medium supplemented
with FBS (2%), L-glutamine (10 mM), heparin sulphate
(0.75 U/ml), VEGF (5 ng/ml), EGF (5 ng/ml), FGF2
(5 ng/ml), IGF-I (15 ng/ml) and ascorbic acid (50 μg/ml)
at 37°C, in a moist atmosphere of 5% CO2. HUVEC were
used for the experiments between passage 2 and 8. All the
experiments were conducted under two different
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in EndoGRO basal medium alone, and stimulated con-
ditions, i.e. with the addition of VEGF (5 ng/ml), EGF
(5 ng/ml), FGF2 (5 ng/ml), IGF-I (15 ng/ml) together
with 10% FBS. In viability, proliferation and migration
assays, cells were used after overnight culture in Endo-
GRO basal medium alone (starvation).
Cell viability
Cell viability assay was performed by flow cytometry.
Briefly, after treatment HUVEC were detached with a
trypsin solution, centrifuged at 600 g for 5 min at room
temperature and the supernatant was finally removed.
The cell pellet was resuspended in 100 μL Binding
Buffer 1× with the addition of 5 μL annexin V (ANX)-
FITC and 5 μL PI, and finally incubated for 15 min at
room temperature in the dark. Samples were stored on
ice and analyzed without washing. Acquisition was per-
formed on a BD FACSCanto II flow cytometer (Becton
Dickinson Italy, Milan, Italy) and data were analyzed
using BD FACSDiva software (version 6.1.3). HUVEC
were identified on the basis of forward-scatter (FSC) and
side-scatter (SSC) properties, and a minimum of 15000
cells for each sample was collected in the gate. Viable,
apoptotic and necrotic HUVEC were identified on a
biparametric plot ANX-FITC vs PI. Data were finally
expressed as% viable (ANX-/PI-), early apoptotic cells
(ANX+/PI-), late apoptotic/necrotic cells (ANX+/PI+)
and necrotic cells (ANX-/PI+).
Proliferation assay
To assess HUVEC proliferation, 1×104 cells were seeded
in duplicate in a 96-well plate and cultured for 24 h
without or with cyclo[DKP-RGD] 1 at different concen-
trations. Proliferation was then measured by a colorimet-
ric immunoassay, based on the ELISA measurement of
bromodeoxyuridine (BrdU) incorporation during DNA
synthesis. The absorbance (ABS) of the samples was de-
termined by means of a spectrophotometer (Model 680,
Bio-Rad Laboratories, Hercules, CA, USA) with wave-
length set at 450 nm, and finally expressed as the differ-
ence between BrdU positive and negative samples,
expressed as Optical Density (O.D.).
Cell migration assay
Cell migration was measured by means of a Boyden
chamber assay. Briefly, 1×105 HUVEC were seeded in
the top well of the Boyden chamber, cyclo[DKP-RGD] 1
was added in the bottom or in the top compartment,
and a 3 μm-pore cellulose nitrate filter was placed be-
tween the two compartments. Stimulated migration was
assessed by putting VEGF, EGF, IGF-I, and FGF2 in the
bottom chamber. After an incubation period of 5 h at
37°C, the filter was recovered, dehydrated, fixed, andfinally stained with hematoxylin. Migration into the filter
was quantified by measuring the distance (in μm) from
the surface of the filter to the leading front of cells using
an optical microscope (Axiolab, Carl Zeiss S.p.A. Milan,
Italy).
Angiogenesis assay
To assess angiogenic activity, HUVEC 2.5×104 cells were
seeded in a 24-well plate coated with 100 μl/well of
Matrigel previously polymerized for 1 h at 37°C. Cells
were then incubated for 5 h at 37°C in a moist atmos-
phere of 5% CO2 without or with cyclo[DKP-RGD] 1
under either resting or stimulated conditions. In some
experiments IL-8 (10 nM) was used as pro-angiogenic
stimulus. Network formation was evaluated by phase‐
contrast microscopy using a fluorescence microscope
(Axiovert 40CFL, Carl Zeiss S.p.A. Milan, Italy). Net-
work formation was finally quantified in terms of mean
number of loops per field as topological parameters and
the total length of the branches. For the purpose of the
analysis, loops were defined as any complete ring formed
by HUVEC, while open ramifications were considered as
branches. The total branch length (pixels) and the num-
ber of loops were quantified using the ImageJ image ana-
lysis software (http://rsbweb.nih.gov/ij/).
Real time PCR
Cells were treated for 5 h in the presence or absence of
1 μM cyclo[DKP-RGD] 1 in different growth conditions,
as previously described. At the end of the treatment,
RNA extraction was performed using the Qiazol lysis re-
agent. Primers were designed by using the “Primer3 input”
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.
cgi/primer3_www.cgi) and the specificity of each primer
was controlled by the BLAST software (http://blast.ncbi.
nlm.nih.gov) (Table 1). Real time PCR was performed as
previously reported [18] At the end of the reaction, a melt-
ing curve analysis was carried out to check for the pres-
ence of primer-dimers. Comparison of the expression of
each gene was determined by using GAPDH as house-
keeping gene. Each run was analyzed in duplicate and data
are finally expressed as 2-Δct.
Western blot analysis
Cells grown in 60-mm dishes were treated for 5 h with
1 μM cyclo[DKP-RGD] 1. The cells were then rinsed twice
in ice-cold PBS and 200 μl of the cell lysis buffer (compos-
ition: 50 mM Tris–HCl pH 7.4, 1% v/v NP40, 0.25% w/v
sodium deoxycholate, 1 mM phenylmethylsulphonyl-
fluoride, 1 mM Na3VO4, 1 mM EDTA, 30 mM sodium
pyrophosphate, 1 mM NaF, 1 mg/ml leupeptin, 1 mg/ml
pepstatin A, 1 mg/ml aprotinin and 1 mg/ml microcystin)
was added to the dishes. After scraping, cells were soni-
cated for 10 s, centrifuged at 12000 g for 5 min at 4°C and
Table 1 Sequences of the primers and PCR products size
Gene Ref. sequence Sequence Product
size
αv NM_002210 Forward: actggcttaagagagggctgtg 110
Reverse: tgccttacaaaaatcgctga
β3 NM_000212 Forward: agacactcccacttggcatc 123
Reverse: tcctcaggaaaggtccaatg
β5 NM_002213 Forward: agcctatctccacgcacact 91
Reverse: cctcggagaaggaaacatca
GAPDH NM_001289746.1 Forward: caactgtgaggaggggagatt 97
Reverse: cagcaagagcacaagaggaag
Fanelli et al. Vascular Cell 2014, 6:11 Page 4 of 9
http://www.vascularcell.com/content/6/1/11the amount of proteins in the supernatant was measured
using the BCA protein assay. For western blot analysis,
20 μg of proteins were separated by 10% SDS–PAGE at
150 V for 2 h and blotted onto 0.22 mm nitrocellulose
membranes at 90 mA for 16 h. The membranes were first
blocked for 2 h in TRIS buffered saline solution (TBST,
composition: TRIS 10 mM, NaCl 150 mM, 0.1% Tween
20) plus 5% low fat dry milk (TBSTM) and then incubated
with the appropriate antibody diluted 1:1000 in TBSTM,
for 16 h at 4°C under gentle agitation. The membranes
were rinsed three times in TBST and then incubated for
2 h at 21°C with the secondary antibody diluted 1:10000
in TBSTM. Membranes were then rinsed three times in
TBST and luminescence was detected by using the appro-
priate kit, and densitometric analysis was performed as
previously reported [18].
Statistical analysis
Data are shown as means ± standard deviation (SD) un-
less otherwise indicated. Statistical significance of the
differences was assessed by two-tailed Student’s t test for
paired data or by One-way analysis of variance followed
by Dunnett’s Multiple Comparison Test as appropriate.
Calculations were performed using a commercial software
(GraphPad Prism version 5.00 for Windows, GraphPad
Software, San Diego California USA, www.graphpad.com).
Results
Viability and apoptosis
Viable cells, measured after 24 h, were 81.7 ± 6.0% in
basal conditions and 90.2 ± 3.7% in the presence of
VEGF, EGF, IGF-I, and FGF2 (n = 4, P = 0.066 vs basal
conditions). Early apoptotic cells were, respectively,
10.8 ± 2.0% and 6.5 ± 3.4% (n = 4, P = 0.117), late apop-
totic/necrotic cells were 5.4 ± 3.5% and 1.7 ± 0.3% (n = 4,
P = 0.082) and necrotic cells were 2.5 ± 1.5% and 1.6 ±
0.8% (n = 4, P = 0.430). The presence of cyclo[DKP-RGD]
1 in the 1×10−12-1×10−6 M did not affect the percentage
of viable, early apoptotic, late apoptotic/necrotic or nec-
rotic cells to any significant extent in either experimentalconditions (with cyclo[DKP-RGD] 1 1×10−6 M, viable
cells: 85.4 ± 3.4% and 86.8 ± 9.2%; early apoptotic cells:
10.5 ± 3.1% and 9.1 ± 7.7%; late apoptotic/necrotic cells:
2.7 ± 0.6% and 2.4 ± 0.9%; necrotic cells: 1.8 ± 0.8% and
1.9 ± 1.1%; in all the cases, n = 4 and P > 0.05 vs control).
Proliferation
HUVEC proliferation in basal conditions was 0.25 ± 0.18
O.D. and increased up to 1.85 ± 0.50 O.D. in the pres-
ence of VEGF, EGF, IGF-I, and FGF2 (n = 3–6, P < 0.05).
Cell incubation with cyclo[DKP-RGD] 1 up to 1×10−5 M
did not significantly affect either basal or stimulated pro-
liferation (data not shown).
Migration
Spontaneous migration of HUVEC was 25.2 ± 9.5 μm
and increased by 87.8 ± 53.7%, up to 44.9 ± 13.4 μm in
the presence of VEGF, EGF, IGF-I, and FGF2 in the bot-
tom chamber (n = 17, P < 0.001 vs basal conditions).
When cyclo[DKP-RGD] 1 was added in the top chamber,
i.e. together with HUVEC, spontaneous migration was in-
creased and stimulated migration was decreased, while
when it was added in the bottom chamber both spontan-
eous and stimulated migration were increased (Figure 2).
Angiogenesis
HUVEC under basal conditions did not show any significant
network formation. Addition of VEGF, EGF, IGF-I, and
FGF2 induced a significant network formation, which was
even higher when cells were treated with IL-8 (Figure 3).
Coincubation with cyclo[DKP-RGD] 1 did not signifi-
cantly affect angiogenesis of HUVEC under basal condi-
tions (Figure 3b-d), however it significantly and profoundly
decreased the effect of VEGF, EGF, IGF-I, and FGF2
(Figure 3 and Figure 4, panel A) as well as the effect of
IL-8 (Figure 3 and Figure 4, panel B).
Expression of mRNA for αv, β3 and β5 integrin subunits
HUVEC expressed comparable amounts of the mRNA
for αv, β3 and β5 integrin subunits in both basal condi-
tions and after treatment with VEGF, EGF, IGF-I, and
FGF2, and coincubation with 1×10−6 M cyclo[DKP-
RGD] 1 did not affect mRNA expression of any of the
subunits in either experimental conditions (Table 2).
Akt phosphorylation
Treatment of HUVEC with 1×10−6 M cyclo[DKP-RGD] 1
in basal conditions reduced phosphorylated Akt, from
16241.7 ± 1763.3 to 8702.7 ± 2008.7 optical density arbitrary
units, down to 53.2 ± 7.9% of control (n = 3, P = 0.001),
without however any significant effect in the presence
of VEGF, EGF, IGF-I, and FGF2 (15406.0 ± 1218.8 to
15174.7 ± 663.9 optical density arbitrary units, n = 3,


































































































basal conditions VEGF + EGF + IGF-I + FGF2 
Figure 2 Effect of cyclo[DKP-RGD] 1 on HUVEC migration in the Boyden chamber assay. Cells were placed in the top compartment. Empty
circles: cyclo[DKP-RGD] 1 placed in the top compartment. Filled circles: cyclo[DKP-RGD] 1 placed in the bottom compartment. Data are means ±





VEGF, EGF, IGF-I, FGF2
Figure 3 Representative phase contrast photomicrographs of HUVEC plated on Matrigel in basal conditions or in the presence of
VEGF, EGF, IGF-I, and FGF2 or IL-8, without and with cyclo[DKP-RGD] 1 at different concentrations.
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Figure 4 Effect of cyclo[DKP-RGD] 1 on HUVEC angiogenesis induced by VEGF, EGF, IGF-I, and FGF2 (upper panels) or IL-8 (lower panels).
Angiogenesis was evaluated as both number of loops (A) and length of branches (B). Empty symbols: basal conditions; filled symbols: stimulated
conditions. Data are means ± SEM of 3–5 separate experiments. # = P < 0.01 vs basal conditions, * = P < 0.01 vs respective control.
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HUVEC represent a valid in vitro model which provides
seminal insights into the cellular and molecular events
leading to neovascularization in response to inflammationand hypoxia in cancer, ischemic events, and in embryo-
genesis [19]. As anticipated in the introduction, integrins
are key actors in angiogenesis and vascular homeostasis,
acting as promoters of endothelial cell-matrix interactions
Table 2 Real time PCR analysis of the expression of
mRNA for the integrin subunits αv, β3 and β5 in HUVEC
cultured for 5 h in basal conditions and with VEGF, EGF,
IGF, and FGF, alone (control) or in the presence of 1 μM
cyclo[DKP-RGD] 1
Subunit control + cyclo[DKP-RGD] 1
2-Δct ×102 2-Δct ×102 Ratio vs Control P vs Control
A. Basal conditions
αv 6.65 ± 6.41 6.59 ± 5.24 1.32 ± 0.57 0.944
β3 0.89 ± 0.87 0.91 ± 0.76 1.08 ± 0.27 0.928
β5 1.36 ± 1.18 1.52 ± 1.34 1.08 ± 0.07 0.225
B. With VEGF, EGF, IGF, and FGF
αv 13.31 ± 12.80 15.09 ± 10.66 1.28 ± 0.42 0.494
β3 1.15 ± 1.07 1.41 ± 1.07 1.43 ± 0.35 0.288
β5 1.23 ± 1.25 1.31 ± 1.13 1.34 ± 0.46 0.461
Data are means ± SD of 3 separate experiments.
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ition of the αvβ3 subtype suppresses angiogenesis in many
experimental models and αvβ3 antagonists (i.e. antibodies,
peptides and peptidomimetics) are being developed as
antiangiogenic drugs [21]. It is known that integrins αvβ3
and αvβ5 are expressed on HUVEC [22]; as a consequence
these cells represent a suitable model to study the effects
of agents acting on such targets. In the present study we
used HUVEC to test the ability of the peptidomimetic in-
tegrin ligand cyclo[DKP-RGD] 1 to affect the key steps of
the angiogenic process by evaluating its effects on prolifer-
ation, migration and capillary-like network formation.
Some of us previously showed that cyclo[DKP-RGD] 1 in-
hibits vitronectin binding to αvβ3 and αvβ5 integrins with
IC50 of 4.5 ± 1.1 nM and 149 ± 25 nM respectively [16].
In our experiments, the effects of cyclo[DKP-RGD] 1
on HUVEC activity were tested in resting conditions as




Figure 5 Western blot analysis of Akt phosphorylation in HUVEC cult
FGF2, alone (control, C) or in the presence of 1 μM cyclo[DKP-RGD] 1with growth factors known to promote angiogenesis
such as VEGF, EGF, IGF-I and FGF2 or after addition of
the pro-inflammatory chemokine IL-8, which has a key
role in the regulation of pathological angiogenesis [2,3].
According to our results, cyclo[DKP-RGD] 1 is indeed
able to strongly inhibit angiogenesis, as indicated by the
reduction of network formation (vide infra), and this oc-
curs without affecting cell viability, apoptosis or prolifer-
ation. Most anti-angiogenic compounds acting through
the inhibition of integrin function, such as cilengitide,
exhibit cytotoxic activity in the same or very close con-
centration range [23]. In our experimental conditions,
our compound did not affect cell viability and apoptosis
or cell proliferation, suggesting that its antiangiogenic
activity is likely independent from cytotoxicity. This lat-
ter observation deserves further consideration because
angiogenesis represents a key step in some pathological
conditions beyond tumour growth. For example ather-
omatous plaque vulnerability is closely related to neoan-
giogenesis [24]; in this latter case a cytotoxic effect
exerted by an antiangiogenic compound could represent
a risk for adverse effects. On the other hand, the lack of
cytotoxic effects by cyclo[DKP-RGD] 1 was also observed
in several different cell-lines such as ovarian carcinoma
IGROV-1 or SKOV3, human pancreatic carcinoma PANC-
1 and MIA-PaCa2, human osteosarcoma U2-OS [25], and
can be considered therefore as a general feature of our
compound. Whether this lack of cytotoxicity might be sug-
gestive of reduced toxicity and increased tolerability in vivo
in different pathological conditions needs to be assessed in
specific studies.
Investigation of the specific mechanisms responsible
for the antiangiogenic effects of cyclo[DKP-RGD] 1 was
beyond the purpose of the present study; nonetheless,
according to our results, this compound did not affect
the mRNA levels for the integrin subunits αv, β3 and β5,C RGD
VEGF + EGF + IGF-I + FGF2
ured for 5 h in basal conditions and with VEGF, EGF, IGF-I, and
(RGD). Data are from one representative of 3 separate experiments.
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inhibited the phosphorylation of Akt, a serine/threonine-
specific protein kinase that plays a key role in the regula-
tion of vascular homeostasis and angiogenesis [17]. The
fact that the inhibition of Akt phosphorylation is only
detected under basal conditions may be explained con-
sidering that, in the presence of growth factors conver-
ging on the same intracellular signalling pathway, the
inhibitory effect exerted by cyclo[DKP-RGD] 1 is prob-
ably overcome. Inhibition of Akt phosphorylation by
cyclo[DKP-RGD] 1 is likely the results of disruption of
proper endothelial cell–extracellular matrix attachment,
due to integrin engagement by cyclo[DKP-RGD] 1. In-
deed, it has already been reported that antagonists
against αvβ3 or αvβ5 integrin interfere with angiogenesis
induced by several growth factors: for instance, αvβ3 in-
tegrin associates with VEGF and platelet-derived growth
factor (PDGF) receptors and potentiates VEGF or PDGF
signaling, respectively [26].
Disruption of integrin functions may possibly explain
also the effects of cyclo[DKP-RGD] 1 on HUVEC migra-
tion. Indeed, in the presence of cyclo[DKP-RGD] 1 mi-
gration was increased in resting conditions but it was
decreased in stimulated conditions when the compound
was added in the top compartment of the Boyden cham-
ber, together with the cells, while it was increased in
both resting and stimulated conditions when the com-
pound was added in the bottom compartment. As a
temptative explanation, we propose that increased mi-
gration results from the direct inhibitory effect of cyclo
[DKP-RGD] 1 on integrins αvβ3 and αvβ5, resulting in
reduced cell anchorage to surfaces. On the other side,
the slight decrease of stimulated migration and the re-
duced increase of spontaneous migration when cyclo
[DKP-RGD] 1 was added in the same compartment in
which the cells were placed might imply also a slight
chemoattractant effect of this compound, which would
therefore not only increase cell random migration
through decreased integrin-mediated attachment to the
surfaces, but also attract the cells along its concentra-
tion gradient. The in vivo relevance of such effect,
where no concentration gradient is expected to occur,
is however questionable. Remarkably, the effect exerted
by cyclo[DKP-RGD] 1 was apparently bell-shaped, with
a peak at about 1×10−9 M (which however was not ob-
served in the angiogenesis assay). Whether this finding
implies different modes of action depending on the ex-
tension of integrin engagement on the cell surface, it
should be established in specific experiments. Disrup-
tion of integrin function could therefore explain both
the increased migration and the anti-angiogenic activity
exerted by cyclo[DKP-RGD] 1. A similar effect was ob-
served by Mrksich and co-workers [27], who promoted
cell migration on self-assembled monolayers containingimmobilized cyclic RGD by addition of exogenous lin-
ear RGD ligands [27].
In our experiments, cyclo[DKP-RGD] 1 effectively
inhibited angiogenesis induced by the growth factors
VEGF, EGF, IGF-I and FGF2, as well as by IL-8. All these
proangiogenic agents act through distinct membrane re-
ceptors [28,29] which result in the activation of exten-
sively overlapping intracellular cascades finally activating
common effector molecules, such as NF-κB or HIF-1
[28]. In addition, recent evidences indicate that direct in-
teractions may occur between integrin activated path-
ways and signalling from VEGF receptors [30] and EGF
receptors [31]. Collectively, in the light of such observa-
tions, our results support the ability of cyclo[DKP-RGD] 1
to block common mechanisms, resulting in the effective
inhibition of angiogenesis triggered by multiple agents.
Angiogenesis is a process that occurs not only in cancer,
but also in many other critical diseases such as athero-
sclerosis [32], and the relevance of cyclo[DKP-RGD] 1-in-
duced effects in such conditions needs careful assessment.
In conclusion, the data of the present study show that
the novel compound cyclo[DKP-RGD] 1, an αvβ3 and
αvβ5 integrin ligand, effectively inhibits angiogenic pro-
cesses in HUVEC, possibly through mechanisms involving
reduced Akt phosphorylation and disruption of integrin-
mediated adhesion, without affecting their viability and
proliferation. We propose therefore this compound as a
candidate modulator of angiogenesis occurring in different
conditions, possibly devoid of the adverse effects of cyto-
toxic analogues. Further studies clarifying the in vivo
activity of cyclo[DKP-RGD] 1, including a complete toxi-
cological assessment, as well as a thorough investigation
of the intracellular pathways involved its effects are cur-
rently underway in order to evaluate its possible potential
applications as a novel pharmacotherapeutic compound.
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